Rhythm Pharmaceuticals, Inc. (RYTM) Stock: Price, Forecast & Analyst Target
Rhythm Pharmaceuticals, Inc. (RYTM) — MoonshotScore 28/100 (Weak band), calculated Nov 18, 2026. Price $119.04 (+2.08%), as of the Nov 18, 2026 trading session; market cap $8.25B. Expected results Feb 25, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 25.71× (cash as of Sep 30, 2026) · expected results Feb 25, 2027
Rhythm Pharmaceuticals, Inc. · RYTM · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13: Rhythm Pharmaceuticals operates as a commercial-stage biotechnology business selling a targeted therapy for rare genetic obesity disorders. Success hinges on whether the company can expand approvals for its sole commercial drug to cover a wider spectrum of genetic weight conditions before its substantial cash reserves dwindle.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Rhythm Pharmaceuticals (RYTM)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Weak quality and a full valuation, though the balance sheet is only middling; the market is already moving on it. The score also carries a risk penalty for losses on top of negative retained earnings. Business Quality: Thin; Financial Safety: Okay; Valuation: Full; Growth Durability: Flat; Momentum: Surging.
- quarterly revenue $51M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 4 of the last 8 reports
- Altman Z 15.41 · Piotroski F 2
Holding back: weak fundamentals
Helping: positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 32 | Weak | |
| 32 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 28 | Weak | |
| 28 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $119.04 | |
| Change on the day | +2.08% | |
| 52-week range | $74.50–$122.20 | |
| Market capitalisation | $8.25B | — |
| Price / earnings (trailing) | -77.70 | |
| Shares traded on the day | 2.01M | |
| Beta (volatility vs the S&P 500) | 2.13 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We expect the restriction to be lifted in November 2027, after which eligible patients may receive prescription supply for up to three months. We anticipate a greater commercial contribution from Japan in the second and third years of launch.
Yann Mazabraud · Statement from
We now anticipate approximately $360 million-$380 million in non-GAAP operating expenses for 2026, comprised of non-GAAP R&D of $165 million-$175 million and non-GAAP SG&A of $195 million-$205 million.
Hunter Smith · Statement from
How to read these dates
A statement's date is the earnings call where it was made, not a deadline. Management expectations and estimated dates can change.
Other perspectives
Council score for Rhythm Pharmaceuticals (RYTM): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Dalio-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Rhythm Pharmaceuticals (RYTM), and what does it report?
Short answer · as of
A biotechnology classification often implies a speculative pipeline bet with no current sales, but Rhythm operates as a commercial entity generating product revenue.
Research dated 2026-09-13.
The business sells a highly specialized treatment for weight conditions stemming from specific genetic deficits.
Consequently, the income statement tracks the adoption curve of this medication among a narrow patient population, weighed against the costs of funding clinical trials to expand the label into related genetic disorders.
What do the latest results show for Rhythm Pharmaceuticals (RYTM)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $51M.
Research dated 2026-09-13.
The most recent income statement shows consecutive sequential revenue growth alongside sustained operating losses. Gross profitability remains notably high, typical of specialized therapeutics, but the cost of commercial operations and ongoing research exceeds total sales.
The expansion in revenue points to widening adoption of its approved medication, yet management continues to guide for heavy operating expenditures focused on global market launches and further clinical research.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $92.13M Sep 30, 2026
- Latest quarter · R&D
- $52.48M Sep 30, 2026
- Latest quarter · SG&A
- $66.75M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- −$39.27M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $92.13M | $52.48M | $66.75M | −$39.27M |
| Jun 30, 2026 | $71.25M | $43.43M | $67.45M | −$48.55M |
| Mar 31, 2026 | $60.11M | $41.73M | $63.59M | −$52.36M |
| Dec 31, 2025 | $57.25M | $42.03M | $57.48M | −$47.06M |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $92.13M Nov 3, 2026
- Latest report · revenue estimate
- $85.56M Nov 3, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 3, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 3, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 3, 2026 | $92.13M | $85.56M | −$0.6100 | −$0.7097 |
| Aug 4, 2026 | $71.25M | $67.66M | −$0.7300 | −$0.8072 |
| May 5, 2026 | $60.11M | $55.78M | −$0.8300 | −$0.8600 |
| Feb 26, 2026 | $57.25M | $56.21M | −$0.7300 | −$0.7900 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $51M | -$53M | -$0.82 (diluted) |
| Q4 FY2025 | $57M | -$48M | -$0.73 (diluted) |
| Q1 FY2026 | $60M | -$56M | -$0.83 (diluted) |
| Q2 FY2026 | $71M | -$49M | -$0.73 (diluted) |
What are the financial strengths and risks for Rhythm Pharmaceuticals (RYTM)?
Short answer
Cash and short-term investments were $320.94M at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$3.06M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
The balance sheet carries minimal debt compared to a substantial holding of cash and short-term investments. This liquidity pool provides a deep runway to fund the current rate of operating cash outflows, giving the clinical teams time to pursue label expansions.
The primary risk lies in the heavy concentration on a solitary active compound; any setback in ongoing trials or commercial uptake would directly impact the entire revenue profile and accelerate cash depletion.
Data-derived red flags
- Negative return on equity (-83.7%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$3.06M Sep 30, 2026
- Previous quarter · operating cash flow
- −$53.34M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | −$3.06M | −$500,000 |
| Jun 30, 2026 | −$53.34M | $0.00 |
| Mar 31, 2026 | −$44.18M | $0.00 |
| Dec 31, 2025 | −$25.39M | −$950,000 |
How to read these figures
Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.
What should you watch next at Rhythm Pharmaceuticals (RYTM)?
Short answer · as of
The next earnings report is expected on Feb 25, 2027.
Research dated 2026-09-13.
Market attention now turns to upcoming regulatory decisions and international expansion efforts, particularly expected approvals in Asian markets.
Investors will monitor the next quarterly filing to see if the sequential revenue growth trend holds against analyst projections of rapid commercial scaling. Additionally, the pace of operating cash consumption will be scrutinized against management expense guidance to ensure the existing liquidity buffer remains sufficient.
What management is planning
What the records here don't tell us
- The newest quarter held here (Q3 FY2025) was filed Nov 4, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Rhythm Pharmaceuticals compare with its peers?
Short answer
Rhythm Pharmaceuticals's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Unlike early-stage pharmaceutical ventures reliant entirely on future pipeline success, this business manages a live commercial rollout while simultaneously conducting mid-stage trials for the same compound.
The focus on ultra-rare genetic pathways for obesity sets it apart from major pharmaceutical firms developing broad-market weight loss treatments. Here, the target patient population is inherently small, meaning revenue growth depends on accurate genetic screening and high treatment pricing rather than mass-market volume.
| Company | Price | Market value | Score |
|---|---|---|---|
| $95.05 Nov 18, 2026 | $7.47B | 98 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $95.80 Nov 18, 2026 | $10.9B | 95 5-pillar Nov 18, 2026 | |
| $72.75 Nov 18, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $67.79 Nov 18, 2026 | $7.42B | 91 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $127.16 Nov 18, 2026 | $8.30B | 88 5-pillar Nov 18, 2026 | |
| $19.50 Nov 18, 2026 | $5.59B | 83 5-pillar Nov 18, 2026 | |
| $298.71 Nov 18, 2026 | $5.98B | 71 5-pillar Nov 18, 2026 | |
| $95.74 Nov 18, 2026 | $6.49B | 67 5-pillar Nov 18, 2026 | |
| $124.86 Nov 18, 2026 | $5.27B | 66 5-pillar Nov 18, 2026 | |
| $156.23 Nov 18, 2026 | $6.35B | 64 5-pillar Nov 18, 2026 | |
| Rhythm Pharmaceuticals (RYTM) — this page | $119.04 | $8.25B | 28 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $120.00 – $160.00
- Consensus target
- $144.43
- Median target
- $154.00
Consensus record · Captured .
Measured against a quoted price of $119.04 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Sep 14, 2026
- Transactions
- 60
- Identified insiders
- 12
- Purchases
- 0
- Sales
- 21
- Other transactions
- 39
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 340 Period end Sep 30, 2026
- Previous quarter · holders
- 315 Prior to period end Sep 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Ra Capital Management, L.P. | 6,666,837 |
| Blackrock, INC. | 5,975,285 |
| Baker Bros. Advisors LP | 5,604,483 |
| Jpmorgan Chase & Co | 3,558,229 |
| Vanguard Portfolio Management LLC | 3,148,914 |
Tracked investors
Which of the 16 named investors we follow held RYTM in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Duquesne Family Office | Stanley Druckenmiller | Q3 2026 | 0.57% | $25.70M | Added +32.6% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Sep 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Rhythm Pharmaceuticals (RYTM)?
- Rhythm Stock Is Up 32%. Is One Drug Enough?
- Rhythm Pharmaceuticals Says Rare Obesity Drug Delivers Sustained Two-Year BMI Reductions
- Rhythm Pharmaceuticals Announces New Clinical Data for Setmelanotide in Acquired Hypothalamic Obesity
- Rhythm Pharmaceuticals Announces Presentation of New Data at ObesityWeek® 2026
Common Questions About RYTM (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Does the revenue mix rely entirely on IMCIVREE?
The income statement attributes all generated revenue to product sales of this specific therapy. The business currently lacks secondary commercial products, tying its entire financial performance to the continued adoption of its lead compound.
How does the company fund its ongoing clinical trials for rare genetic obesity?
Operations and research are financed by drawing down a large reserve of cash and short-term investments, which management maintains is sufficient for multiple future reporting periods. While product revenue is growing rapidly, it remains insufficient to cover the total costs of commercialization and pipeline expansion.
Are insiders currently building larger positions in the stock?
Recent regulatory filings show executives disposing of more shares than they are acquiring on the open market. These transactions include routine dispositions related to equity awards alongside exempt liquidations, resulting in a net reduction of insider holdings over the recent observation window.
What clinical or commercial milestones is management targeting next?
Executives project an upcoming regulatory approval for acquired hypothalamic obesity, alongside a targeted market launch in Japan. These milestones are intended to broaden the addressable patient base for the existing therapy without requiring an entirely new drug discovery process.
What is the RYTM stock price today?
The last price recorded for Rhythm Pharmaceuticals, Inc. (RYTM), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RYTM price target?
The analyst consensus price target for Rhythm Pharmaceuticals, Inc. (RYTM), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 79 figures on this page — 1 from SEC filings and earnings calls, 70 from Financial Modeling Prep (FMP), 4 with no recorded source, 3 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com